Moderna, Inc. cash flow to debt ratio of -97.76% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Moderna, Inc.'s free cash flow has increased -49.08% from $-4.05B last year to $-2.06B, signaling increasing performance

Moderna, Inc.'s debt to equity ratio is 0.19, which means that the company's assets are healthy financed, signaling financial stability.

Moderna, Inc.'s debt has increased relative to shareholder equity from 0.07 last year to 0.19 today, signaling weakened financials

Moderna, Inc. has a net cash position, so leverage is healthy.

Moderna, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Moderna, Inc.'s profit margin has decreased (27.05%) in the last year from -111.32% to -141.43%, signaling decreasing performance

Moderna, Inc.'s short-term assets of $6.54B exceed its short-term liabilities of $1.99B

Moderna, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Moderna, Inc.'s return on equity of -39.20%, is lower than 15.00%, indicating bad performance

Moderna, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Moderna, Inc. had positive net income in only 2 out of 5 years, indicating unstable earnings

Moderna, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Moderna, Inc. has negative free cash flow, indicating cash burn

Moderna, Inc.'s yearly earnings has increased -20.75% since last year from $-3.56B to $-2.82B, signaling increasing performance

Moderna, Inc.'s yearly revenue has decreased 39.23% since last year from $3.20B to $1.94B, signaling decreasing performance

ROIC -39.16% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Moderna, Inc.'s 3-year revenue CAGR of -53.13% is negative, indicating declining revenue over the past 3 years

Moderna, Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Moderna, Inc. had positive ROE in only 2 out of 5 years, indicating inconsistent returns on equity

Moderna, Inc. has insufficient data to evaluate this check.

Moderna, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Moderna, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Moderna, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Moderna, Inc. is overvalued relative to its fair value price of -59.87 based on Earnings Fair Value model

Moderna, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Moderna, Inc. has a price-to-book ratio of 3.50x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Moderna, Inc. has a price-to-sales ratio of 10.63x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue